What are the market access obstacles that are shaping the US asthma/COPD inhalables market and which brands are winning out?
High cost, no formulary listing and stock availability are just some of the barriers that can negatively influence prescribing volumes and exert downward pressure on profitability. What market access barriers are influencing physicians’ therapy choices and how is this determining market share?
This and other key questions are answered in this insightful June 2019 analysis of 9 leading asthma/COPD inhalables brands. Based on the results of an in-depth survey of 100 US-based allergists and pulmonologists, Market Access Impact (US): Asthma/COPD Inhalables identifies the market access barriers that are shaping the competitive landscape for leading asthma/COPD inhalables brands in the US and provides clear pointers for management action.
Evaluating leading companies in the US asthma/COPD inhalables sector
Leading brands covered in this report
Answering important market access questions
Market access barriers examined in this survey
Exclusive to FirstView, Market Access Impact surveys reveal the barriers that influence prescribing, identify the brands that win or lose market share, and highlight the
brand-specific market access challenges that management must overcome
The experience of the physicians surveyed
This detailed analysis is based on a survey of 100 US allergists and pulmonologists with a wealth of experience treating asthma/COPD inhalables. On average they:
This report gives you...
Why FirstView has an edge in pharmaceutical market research
FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.
Other ASTHMA/COPD INHALABLES reports available
Market Access Impact (Europe): Asthma/COPD Inhalables
Medical Affairs Reputations (US): Asthma/COPD Inhalables
Medical Affairs Reputations (Europe): Asthma/COPD Inhalables
NPS+ US: Asthma/COPD Inhalables
NPS+ Europe: Asthma/COPD Inhalables
Therapy Trends KOL Insight: Targeted Therapies in Severe Asthma
Therapy Trends KOL Insight: COPD
To learn about our cost effective Asthma/COPD Inhalables intelligence package of all reports, please contact us at info@fwreports.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved